QBank Fortnightly Newsletter

Volume 1, Issue 3

Hello there!

Thank you for the overwhelming response to our previous issues. 

We continue to bring more interesting updates that have happened in the Qbank. In the current issue of our newsletter, we focus on MCQs that we have revised based on recent drug approvals and withdrawals. 

APPROVALS AND WITHDRAWALS

The drugs listed below have been recently approved or withdrawn by the FDA. This is not an exhaustive list:

1. Ripretinib: 

A novel, oral, pan-KIT, and PDGFRα kinase inhibitor, approved for adult patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Source: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf

2. Gardasil 9: 

A Human Papillomavirus nano-valent recombinant vaccine recently received expanded indication that now includes the prevention of oropharyngeal and other head and neck cancers caused by HPV types 6,11,16,18,31,33,45,52,58.

Source: https://www.fda.gov/media/138949/download

3. Celecoxib: 

A non-steroidal anti-inflammatory drug, approved for the treatment of acute migraine with or without aura in adults. It is not indicated for the preventive treatment of migraine.

Mechanism of action: Inhibition of prostaglandin synthesis, primarily via inhibition of cyclooxygenase-2 (COX-2), at therapeutic concentrations.
Note– It does not inhibit the cyclooxygenase-1 (COX-1) isoenzyme.                          

Source: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212157s000lbl.pdf

4. Tucatinib:  

A Tyrosine kinase inhibitor of HER2, approved for the treatment of HER-2 positive breast cancer in combination with Trastuzumab and Capecitabine for the treatment of unresectable and metastatic cases.

Source: https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-drug-under-international-collaboration-treatment-option-patients-her2

5. Ustekinumab: 

A human interleukin-12 and -23 antagonist recently approved for the treatment of moderate to severe cases of ulcerative colitis available as an injection, for subcutaneous or intravenous use.

Other indications are plaque psoriasis, Chron’s disease, and Psoriatic arthritis.

Source: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761044s003lbl.pdf

6. Dolutegravir:

The FDA approved oral Dolutegravir tablets and tablets for suspension for the treatment of HIV-1 infection in pediatric patients at least 4 weeks old, and weighing at least 3 kg, in combination with other antiretroviral treatments.

Source: https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-infants-and-children-hiv#:~:text=Today%2C%20the%20U.S.%20Food%20and,combination%20with%20other%20antiretroviral%20treatments.

7. Ranitidine: 

The FDA has requested the withdrawal of all Ranitidine products due to the presence of a contaminant known as N-Nitrosodimethylamine (NDMA). NDMA at sustained higher levels of exposure may increase the risk of cancer in humans.

Source: https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market

MCQ IDs of the updated MCQ in the QBank: MB2482| MB5010| MC 3578| MB9222| MB2883| MC2235| MB2490| MC0361| MA6533| MB6444

You can copy the MCQ IDs and search for it in the App